Emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United States

Abstract Clonal hematopoiesis (CH) is a risk factor for the development of therapy-related myelodysplastic syndromes (tMDS) and acute myeloid leukemia (tAML). Adoption of targeted-immunotherapeutics since 2011, may alter the risk of CH progression to tMDS/AML. To study this, we evaluated risk of tMD...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Abhay Singh, Megan M. Herr, Elizabeth A. Griffiths, Amanda Przespolewski, Mark G. Faber, Chebli Mrad, Eunice S. Wang, Theresa Hahn, Swapna Thota
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/ad170899005a44ae897c0ca8999eacac
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ad170899005a44ae897c0ca8999eacac
record_format	dspace
spelling	oai:doaj.org-article:ad170899005a44ae897c0ca8999eacac2021-12-05T12:14:05ZEmerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United States10.1038/s41598-021-02497-42045-2322https://doaj.org/article/ad170899005a44ae897c0ca8999eacac2021-12-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-02497-4https://doaj.org/toc/2045-2322Abstract Clonal hematopoiesis (CH) is a risk factor for the development of therapy-related myelodysplastic syndromes (tMDS) and acute myeloid leukemia (tAML). Adoption of targeted-immunotherapeutics since 2011, may alter the risk of CH progression to tMDS/AML. To study this, we evaluated risk of tMDS and tAML in 667 588 ≥ 1-year survivors of non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), melanoma and multiple-myeloma (MM) diagnosed during: 2000–2005, 2006–2010 and 2011–2016. The risk of tMDS increased significantly after NSCLC across all time periods (Ptrend = 0.002) while tAML risk decreased from 2006–2010 to 2011–2016, coinciding with increasing use of non-chemotherapeutic agents. tAML risk after RCC decreased (Ptrend = 0.007) whereas tMDS risk did not significantly change over time. After melanoma, tMDS and tAML risks were similar to the general population. tMDS and tAML risk after MM increased from the first to second time-period, however, only risk of tMDS decreased during last period. We report diverging trends in the risk of tAML and tMDS after adoption of modern cancer therapies for specific cancers. It is imperative to further explore impact of contemporary treatment strategies on clonal evolution. Modern treatments via their discrete mechanism of actions on pre-existing CH may alter the risk of subsequent tMDS and tAML.Abhay SinghMegan M. HerrElizabeth A. GriffithsAmanda PrzespolewskiMark G. FaberChebli MradEunice S. WangTheresa HahnSwapna ThotaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Abhay Singh Megan M. Herr Elizabeth A. Griffiths Amanda Przespolewski Mark G. Faber Chebli Mrad Eunice S. Wang Theresa Hahn Swapna Thota Emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United States
description	Abstract Clonal hematopoiesis (CH) is a risk factor for the development of therapy-related myelodysplastic syndromes (tMDS) and acute myeloid leukemia (tAML). Adoption of targeted-immunotherapeutics since 2011, may alter the risk of CH progression to tMDS/AML. To study this, we evaluated risk of tMDS and tAML in 667 588 ≥ 1-year survivors of non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), melanoma and multiple-myeloma (MM) diagnosed during: 2000–2005, 2006–2010 and 2011–2016. The risk of tMDS increased significantly after NSCLC across all time periods (Ptrend = 0.002) while tAML risk decreased from 2006–2010 to 2011–2016, coinciding with increasing use of non-chemotherapeutic agents. tAML risk after RCC decreased (Ptrend = 0.007) whereas tMDS risk did not significantly change over time. After melanoma, tMDS and tAML risks were similar to the general population. tMDS and tAML risk after MM increased from the first to second time-period, however, only risk of tMDS decreased during last period. We report diverging trends in the risk of tAML and tMDS after adoption of modern cancer therapies for specific cancers. It is imperative to further explore impact of contemporary treatment strategies on clonal evolution. Modern treatments via their discrete mechanism of actions on pre-existing CH may alter the risk of subsequent tMDS and tAML.
format	article
author	Abhay Singh Megan M. Herr Elizabeth A. Griffiths Amanda Przespolewski Mark G. Faber Chebli Mrad Eunice S. Wang Theresa Hahn Swapna Thota
author_facet	Abhay Singh Megan M. Herr Elizabeth A. Griffiths Amanda Przespolewski Mark G. Faber Chebli Mrad Eunice S. Wang Theresa Hahn Swapna Thota
author_sort	Abhay Singh
title	Emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United States
title_short	Emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United States
title_full	Emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United States
title_fullStr	Emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United States
title_full_unstemmed	Emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United States
title_sort	emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the united states
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/ad170899005a44ae897c0ca8999eacac
work_keys_str_mv	AT abhaysingh emergingtrendsoftherapyrelatedmyeloidneoplasmsfollowingmoderncancertherapeuticsintheunitedstates AT meganmherr emergingtrendsoftherapyrelatedmyeloidneoplasmsfollowingmoderncancertherapeuticsintheunitedstates AT elizabethagriffiths emergingtrendsoftherapyrelatedmyeloidneoplasmsfollowingmoderncancertherapeuticsintheunitedstates AT amandaprzespolewski emergingtrendsoftherapyrelatedmyeloidneoplasmsfollowingmoderncancertherapeuticsintheunitedstates AT markgfaber emergingtrendsoftherapyrelatedmyeloidneoplasmsfollowingmoderncancertherapeuticsintheunitedstates AT cheblimrad emergingtrendsoftherapyrelatedmyeloidneoplasmsfollowingmoderncancertherapeuticsintheunitedstates AT euniceswang emergingtrendsoftherapyrelatedmyeloidneoplasmsfollowingmoderncancertherapeuticsintheunitedstates AT theresahahn emergingtrendsoftherapyrelatedmyeloidneoplasmsfollowingmoderncancertherapeuticsintheunitedstates AT swapnathota emergingtrendsoftherapyrelatedmyeloidneoplasmsfollowingmoderncancertherapeuticsintheunitedstates
_version_	1718372150877880320

Emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United States

Ejemplares similares